This company listing is no longer active
Clover Biopharmaceuticals Crecimiento futuro
Future controles de criterios 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Clover Biopharmaceuticals.
Información clave
n/a
Tasa de crecimiento de los beneficios
190.4%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 39.9% |
Tasa de crecimiento de los ingresos | 47.9% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 27 Jul 2023 |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2025 | 2,341 | N/A | N/A | N/A | 1 |
12/31/2024 | 3,071 | N/A | N/A | N/A | 2 |
12/31/2023 | 2,571 | N/A | N/A | N/A | 2 |
6/30/2023 | 0 | -665 | N/A | N/A | N/A |
3/31/2023 | 0 | -1,559 | N/A | N/A | N/A |
12/31/2022 | N/A | -2,452 | -1,796 | -1,691 | N/A |
9/30/2022 | N/A | -4,145 | -1,461 | -1,356 | N/A |
6/30/2022 | N/A | -5,838 | -1,125 | -1,021 | N/A |
3/31/2022 | N/A | -5,927 | -1,062 | -969 | N/A |
12/31/2021 | N/A | -6,016 | -998 | -918 | N/A |
12/31/2020 | N/A | -913 | 363 | 477 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if 2197's forecast earnings growth is above the savings rate (1.9%).
Beneficios vs. Mercado: Insufficient data to determine if 2197's earnings are forecast to grow faster than the Hong Kong market
Beneficios de alto crecimiento: Insufficient data to determine if 2197's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: 2197's revenue (47.9% per year) is forecast to grow faster than the Hong Kong market (8.7% per year).
Ingresos de alto crecimiento: 2197's revenue (47.9% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 2197's Return on Equity is forecast to be high in 3 years time